Literature DB >> 15708742

Osteolytic bone diseases: physiological analogues of bone resorption effectors as alternative therapeutic tools.

Dominique Heymann1, Yannick Fortun, Francoise Rédini, Marc Padrines.   

Abstract

The recent identification of key molecular protagonists involved in osteoclast biology has led to the development of new therapeutic approaches of osteolytic diseases using biological molecules which could compete with bisphosphonate therapy.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15708742     DOI： 10.1016/S1359-6446(04)03265-9

Source DB:  PubMed          Journal:  Drug Discov Today        ISSN： 1359-6446            Impact factor:   7.851


  5 in total

1.  Boric Acid Inhibits RANKL-Stimulated Osteoclastogenesis In Vitro and Attenuates LPS-Induced Bone Loss In Vivo.

Authors:  Bingbing Xu; Fanhe Dong; Pei Yang; Zihan Wang; Ming Yan; Jian Fang; Yun Zhang
Journal:  Biol Trace Elem Res       Date:  2022-04-09       Impact factor: 3.738

2.  Astragalus polysaccharide attenuates LPS-related inflammatory osteolysis by suppressing osteoclastogenesis by reducing the MAPK signalling pathway.

Authors:  Jianye Yang; Leilei Qin; Jiaxing Huang; Yuwan Li; Sha Xu; Hai Wang; Sizheng Zhu; Jiawei Wang; Bo Zhu; Feilong Li; Wei Huang; Xuan Gong; Ning Hu
Journal:  J Cell Mol Med       Date:  2021-06-02       Impact factor: 5.310

Review 3.  Anti-RANKL therapy for bone tumours: Basic, pre-clinical and clinical evidences.

Authors:  Dominique Heymann
Journal:  J Bone Oncol       Date:  2012-04-26       Impact factor: 4.072

4.  Diallyl disulfide alleviates inflammatory osteolysis by suppressing osteoclastogenesis via NF-κB-NFATc1 signal pathway.

Authors:  Jing Yang; Ruohui Tang; Jin Yi; Yueqi Chen; Xianghe Li; Tao Yu; Jun Fei
Journal:  FASEB J       Date:  2019-03-11       Impact factor: 5.191

5.  The protective effect of WKYMVm peptide on inflammatory osteolysis through regulating NF-κB and CD9/gp130/STAT3 signalling pathway.

Authors:  Junxian Hu; Xianghe Li; Yueqi Chen; Xinyun Han; Li Li; Zhengwei Yang; Lianli Duan; Hongwei Lu; Qingyi He
Journal:  J Cell Mol Med       Date:  2019-12-14       Impact factor: 5.310
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.